AMED Amedeo Res

RNS No 4471q                                     
CHIROSCIENCE GROUP PLC
2nd December 1998 
                                     
                                     
                ChiroTech and CombiChem Form Joint Venture
         To Commercialize Single-Isomer Chiral Compound Libraries
 
London  2nd  December, 1998 Chirotech Technology Limited ("ChiroTech"),  a
member  of  the Chiroscience Group of companies (LSE: CRO), and CombiChem,
Inc.  ("CombiChem")  (Nasdaq NMS: CCHM)  are  today  announcing  that  the
companies  have  signed  a joint venture agreement establishing  ChiroChem
Discovery  Services LLC, a San Diego-based company which will develop  and
sell  specifically designed chemical libraries under the  ChiroChem  name.
Under the agreement, ChiroTech will provide novel, multi-functional chiral
templates  which  will be used by CombiChem scientists as  an  information
base  to design and synthesize information-rich chiral compound libraries.
These ChiroChem libraries will be marketed by ChiroTech's salesforce to  a
worldwide   customer  base  focused  on  the  life  sciences   industries.
Operations  of  the  new  joint entity will  be  equally  funded  by  both
companies and revenues will be shared equally.  The financial terms of the
agreement are not being disclosed.
 
Dr  Alan  Shaw,  Managing  Director  of ChiroTech,  commented,  "ChiroChem
Discovery Services will be the first dedicated supplier of quality, single-
isomer  chiral  libraries  and will provide  its  customers  with  greater
structural  activity  and  selectivity  information  for  their  discovery
programs.   In   CombiChem,  ChiroTech  has  a  quality  partner   already
established in the field of computational drug design."
 
"This  joint venture represents an important, new avenue for CombiChem  to
offer  combinatorial  libraries and generate near-term  revenues,"  stated
Vince  Anido,  Jr.,  Ph.D.,  President  and  Chief  Executive  Officer  of
CombiChem.  "ChiroTech, as the leader in chiral technologies, provides the
ideal   complementary   technologies   to   our   design   and   synthesis
capabilities."
 
For further information contact:
Dr Alan Shaw, Managing Director      Giles Sanderson
of ChiroTech                         Financial Dynamics
Christine Soden, Finance Director    Tel: +44 (0)171 831 3113
of Chiroscience Group
Tel: +44 (0)1223 420430
http://www.chiroscience.com
                                     
Notes to Editors:
 
Chirotech  Technology Limited, based in Cambridge UK, is  an  acknowledged
world  leader in the provision of chiral technology, products and services
to  the  life  sciences  industries. Its established  portfolio  includes;
ChiroChem  Collection,  a catalogue of novel chiral  building  blocks  for
discovery   and  early  development;  ChiroSure,  contract  R&D  services;
ChiroCats,  proprietary catalysts and ligands; and, through  its  alliance
with  Mitchell  Cotts  Chemicals  UK, the  provision  of  advanced  chiral
intermediates and active pharmaceutical ingredients at multi-tonne scale.
 
Chirotech  Technology Limited is 70% owned by Chiroscience Group  plc  and
30%  by Ascot PLC who acquired their shareholding in the business for  #30
million on September 1, 1998.  At the same time ChiroTech entered  into  a
formal  manufacturing  alliance  with Mitchell  Cotts  Chemicals  Limited,
Ascot's  fine chemicals manufacturing subsidiary based in West  Yorkshire,
UK.
 
CombiChem,  Inc., based in San Diego, California, is a computational  drug
discovery  company that is applying its proprietary design technology  and
rapid  synthesis capabilities to accelerate the discovery process for  new
drugs.   CombiChem  believes  that  its  approach  offers  pharmaceutical,
biotechnology and agrochemical companies the opportunity to conduct  their
discovery  efforts in a more productive and cost effective manner.   Using
its  proprietary  Discovery  Engine  process,  CombiChem  focuses  on  the
generation,  evolution  and optimization of new lead  candidates  for  its
collaborative  partners, who will then develop, manufacture,  market,  and
sell  the  resulting  products.  CombiChem has  established  collaborative
agreements  with Athena Neuroscience, Inc., a wholly owned  subsidiary  of
Elan  Corporation,  plc., ICOS Corporation, ImClone Systems  Incorporated,
Novartis  Crop  Protection AG, Roche Bioscience, Sumitomo  Pharmaceuticals
Co., Ltd., and Teijin Limited.
 
Chiroscience  Group plc is an emerging pharmaceutical company  which  uses
its  diverse  technology platform to discover and develop novel  medicines
for  improved healthcare.  It is listed on the London Stock Exchange.  The
Group  has  three  principal activities: Chiroscience R&D;  Rapigene;  and
ChiroTech.
 
The  Chiroscience R&D drug discovery and development activities are  based
in  Cambridge  and Stevenage, England, and Seattle, Washington,  USA   and
encompass  skills from gene-based target research  and molecular  biology,
through  chiral-based, combinatorial, medicinal, and process  chemistries,
to  clinical development and registration.  The focus of activities is  on
the  discovery  and  development of innovative small  molecule  drugs  and
related  diagnostics  with  a therapeutic focus on  cancer,  inflammation,
pain, osteoporosis and autoimmune diseases.
 
Rapigene is involved in the creation and provision of genomic technologies
and  services  to partner companies and to Chiroscience's  drug  discovery
programmes.   Its DNA analysis systems comprise of DNA hybridization,  DNA
arrays and mass spectrometry tags.
 
END 

JVEAAAWKWUKURAA

Grafico Azioni Amedeo Res (LSE:AMED)
Storico
Da Giu 2024 a Lug 2024

Grafico Azioni Amedeo Res (LSE:AMED)
Storico
Da Lug 2023 a Lug 2024